Phathom Pharma Upgraded by Barclays to Overweight $18 Target
Barclays lifts Phathom Pharmaceuticals to Overweight with an $18 target, citing a stronger 2026 revenue trajectory an...
This guide explains how to assess different accounts to maximize yields for your emergency fund in 2026 while maintaining liquidity.
27,516 articlesBarclays lifts Phathom Pharmaceuticals to Overweight with an $18 target, citing a stronger 2026 revenue trajectory an...
As Insight (NSIT) reports Q1 2026 results, investors seek clarity on revenue drivers and margins. This guide breaks d...
REMAX Select reports a sharp rise in transaction sides driven by collaboration across markets, earning a top-10 place...
Power Solutions International posted a softer-than-expected Q1 2026, with revenue miss and shrinking margins. Data-ce...
Apple’s 2026 strategy centers on Services and cash returns, contrasting with Amazon’s AI infrastructure push, shaping...
Arweave's AR token is in focus as investors map a path for 2025 through 2030. This piece outlines the key drivers, sc...
China’s DeepSeek AI forecasts notable upside for XRP, PEPE, and Shiba Inu through 2026, highlighting potential cataly...
Ford faces a turning point as it expands EV capabilities while navigating a volatile market. Here are three scenarios...
Realty Income is set to report Q4 2025 results after the close, with investors focused on whether the company maintai...
Investors often chase Berkshire Hathaway's stock picks, but the real driver of lasting success is the company’s opera...
Oil trades around the $100 barrel mark as investors seek safety. This piece identifies a top defensive ETF and explai...
Cash flow from senior housing and warehouse REITs is holding steady even as refinancing costs rise. The payout outloo...